Cohort profile: Mothers who use substances and their children in British Columbia, Canada Authors: Lindsay A. Wilson, Noah Katsuno, Megan Kurz, Nicole Catherine, Shannon Joyce, Brittany Barker, Brittany B. Dennis, Sarah Moreheart, Lianping Ti, Jane A. Buxton, Bohdan Nosyk, David Zhu, David Zhu, David Zhu Published: 2026 ABSTRACT IntroductionPerinatal substance use is a growing public health challenge in the province of BC. A population-based cohort was established using linked health administrative data to underpin three research studies that will evaluate: 1) the effectiveness of specialized acute care for pregnant people who use substances; 2) the comparative effectiveness of different medication regimens for the treatment of perinatal opioid use disorder (OUD); and 3) the longitudinal association between maternal substance use and child health outcomes.MethodsThe population-based cohort includes all individuals in British Columbia (BC), Canada, who delivered an infant from April 1, 2000–March 31, 2022, and who had an indication of substance use in their health administrative records between one year prior to the first pregnancy-related healthcare contact and time of delivery. Individual-level data for mothers and children were linked across ten population-level databases, which include information on demographics, healthcare utilization, drug dispensations, incarceration in provincial prisons, maternal and newborn health outcomes, receipt of housing and income assistance, and deaths and underlying causes.ResultsWe identified 38,670 mothers with substance use disorders and their children (n = 45,823), with a median of 9 (interquartile range: 5–15) years of follow-up available. At the time of delivery, mothers ranged from <19–45 years of age. High levels of morbidity and mortality were documented among both mothers and their children.DiscussionThe growing population of mothers with substance use disorder represent a critical need for the province of British Columbia. This population-based retrospective cohort will be used to inform service design and otherwise advocate for client needs. Introduction Substance use during pregnancy and post-partum (hereafter known as perinatal substance use [PSU]) is associated with increased risk of several adverse maternal, fetal, and neonatal health outcomes, including drug poisonings (i.e., drug overdose), [1,2] pregnancy loss, stillbirth, preterm birth, and maternal and neonatal mortality.[3,4] Over the past two decades, the incidence of PSU has increased substantially across North America.[3,5–8] Similarly, rates of unregulated drug poisonings among pregnant and post-partum people have been rising since 2007.[9–12] From 2018–2021 alone, the drug poisoning mortality ratio among pregnant and post-partum people in the United States aged 35–44 more than tripled, from 4.9 to 15.9 per 100,000 pregnant people.[12] Rates of PSU are particularly high in British Columbia (BC), Canada. Between 2000 and 2020, the incidence of PSU in BC rose from 126 to 247 per 100,000 births.[13] Additionally, a 2021 study concluded that rates of perinatal opioid use disorder (OUD) in BC had risen by 110% since 2001.[6] Results from a 2024 study suggest that overdose is now a major cause of death among pregnant and postpartum people in BC, and these deaths may be underreported.[14] Comprehensive, integrated care models that incorporate both obstetric and addiction medicine services are essential to improving outcomes for pregnant people who use substances and their infants. These models include coordinated access to opioid agonist therapy (OAT), support for rooming-in practices that promote maternal-infant bonding, and continuity of care during the postpartum period. Such approaches improve maternal and neonatal health outcomes, reduce stigma, and enhance engagement in prenatal and addiction care.[15–19] However, these services are inaccessible for many people in BC, due to the lack of providers experienced in addiction medicine, insufficient OAT provider availability, and the dearth of specialized care for pregnant people who use substances.[5,20] These challenges are especially pronounced in rural and remote locations, and for pregnant people experiencing multiple forms of oppression (e.g., gender and racial minority groups), for whom stigma and the risk of child apprehension are particularly high.[5,20,21] This forced parent-child separation is associated with substantial harms for both parents and children, including increased risk of depression, anxiety, drug use, overdose, and suicidal behavior.[22–25] All these findings highlight the urgent need for high-quality population-level research that can inform interventions designed to support improved health outcomes among people with PSU and their children. However, PSU has historically been under-researched and underreported due to ethical concerns around studying this marginalized population [26,27] and healthcare system failures to reach and engage individuals with PSU.[28,29] The few studies that do exist are often limited by small sample sizes and a lack of adjustment for confounding.[30] To address this research gap, a population-based provincial cohort that links mothers with an indication of substance use within 12 months prior to first pregnancy-related healthcare contact and their children was established in 2019. For the purposes of this cohort, the umbrella term “mother” encompasses birthing parents of all gender identities, recognizing that this term unintentionally promotes cisnormativity.[31] This cohort will serve as a foundation for three research studies. The objectives of these studies are: 1. To evaluate maternal and neonatal health outcomes among mother-infant dyads who accessed specialized inpatient PSU programs during pregnancy. 1. To evaluate maternal and neonatal health outcomes among mother-infant dyads who accessed specialized inpatient PSU programs during pregnancy. 2. To evaluate the comparative effectiveness of OAT medications and dosing regimens during pregnancy on maternal and neonatal health outcomes. 2. To evaluate the comparative effectiveness of OAT medications and dosing regimens during pregnancy on maternal and neonatal health outcomes. 3. To evaluate the longitudinal relationship between the health of mothers with PSU and the health outcomes of their children over 20 years of follow-up. 3. To evaluate the longitudinal relationship between the health of mothers with PSU and the health outcomes of their children over 20 years of follow-up. Methods In BC, all contacts with the healthcare system are collected within population-level databases. The cohort was extracted from 10 linked population-level administrative databases: client roster (demographics), the Medical Services Plan (physician billing), the Discharge Abstract Database (hospitalizations), PharmaNet (drug dispensations), BC Corrections (incarceration in provincial prisons), the National Ambulatory Care Reporting System (emergency department visits), the Perinatal Services BC database (maternal and newborn health for all provincial births), the Social Development and Poverty Reduction (SDPR) database (receipt of housing and income assistance), Vital Statistics (deaths and underlying causes), and the BC Coroners Service database (unregulated drug poisoning deaths) (S1 Table and S2 Table). Using unique, de-identified personal health numbers, each mother’s health record is also linked to the records of their children. Using these datasets, we identified all pregnant people with ≥1 indication of substance use (i.e., opioids, alcohol, cannabis, stimulants, sedatives, hypnotics, hallucinogens, or other unspecified substances) between 12 months prior to first pregnancy-related healthcare contact and date of delivery, and who delivered an infant in BC between April 2000–March 2022. As contact with the healthcare system may be relatively infrequent for many people, and in the absence of urine drug testing to confirm substance use, the timeframe of 12 months prior to first pregnancy-related healthcare contact was chosen in an effort to capture ongoing, active substance use at the time of pregnancy. Nicotine and caffeine use was not evaluated in this cohort. Indications of substance use were identified with a case-finding algorithm our team previously developed using Drug Identification Numbers and ICD-9/10-CA codes (S2 Table).[32] Eligible deliveries were those that occurred at ≥20 weeks’ gestation (including stillbirths), as mother-infant linkage and birth records are not included in the Perinatal Services BC database prior to this point. As of July 2025, the provincial cohort included 38,670 mothers with an indication of substance use, and 45,823 children born to these individuals (Fig 1). Cohort Flow Diagram. Follow-up time For each individual in the population-based cohort, longitudinal data are available from one year prior to first pregnancy-related healthcare contact until end of data capture (currently December 31, 2022). Using each mother’s unique personal health number, individually linked data on demographics and geographic location, physician billing, hospitalization, drug dispensation, and death records are available for the years 1996 − 2022. Data on prenatal care and birth outcomes are available from 2000 − 2022, incarceration, unstable housing, and income assistance data are available from 2010 − 2022, and data on emergency department admissions are available from 2012–2022 (S1 Fig). Data are updated annually. Individuals were deemed administratively lost to follow-up if they had no record of death at the end of data capture, and no records in the linked health administrative databases for a ≥ 66-month period prior to the end of study follow-up. This cut-off period was empirically determined based on gaps between encounters with the healthcare system captured in our dataset. The chosen cut-off period of 66 months corresponds with the 97.5th percentile in gap times observed in the cohort.[30,32] Median years of follow-up for mothers in the population-based cohort was 9 (interquartile range [IQR]: 5 − 15) (Table 1). A total of 1,432 mothers (3.7%) and 1,466 children (3.2%) were lost to follow-up and were administratively censored. 10.1371/journal.pone.0348262.t001Table 1Descriptive statistics of mothers in BC with indication of substance use between one year prior to first pregnancy-related healthcare contact and date of delivery, by substance type (2000/04/01-2022/12/31*).Any substancesOpioidsAlcohol onlyCannabis onlyOther substances1(N = 38,670)(n = 3,803)(n = 7,781)(n = 12,329)(n = 14,757) Demographic characteristics Age at delivery, years (median, IQR)27 (22 –32)28 (24 –32)28 (23 –33)27 (23 –32)26 (22 –31)<192990 (7.7%)148 (3.9%)554 (7.1%)809 (6.6%)1,479 (10.0%)19-2412236 (31.6%)1,025 (27.0%)2,026 (26.0%)3,998 (32.4%)5,187 (35.2%)25-3418560 (48%)2,074 (54.5%)3,907 (50.2%)6,134 (49.8%)6,445 (43.7%)>=354876 (12.6%)556 (14.6%)1,290 (16.6%)1,388 (11.3%)1,642 (11.1%)Rural region, n (%)9227 (23.9%)456 (12.0%)2,358 (30.3%)3,028 (24.6%)3,385 (22.9%)Ever received income assistance, n (%)18655 (48.2%)3,035 (79.8%)2,198 (28.3%)5,450 (44.2%)7,972 (54.0%)Ever experience unstable housing, n (%)1309 (3.4%)581 (15.3%)71 (0.9%)202 (1.6%)455 (3.1%)Ever incarcerated, n (%)1408 (3.6%)728 (19.1%)62 (0.8%)78 (0.6%)540 (3.7%)Died during follow-up, n (%)1387 (3.6%)358 (9.4%)245 (3.2%)85 (0.7%)699 (4.7%)Years of follow-up included (median, IQR)9 (5 –15)8 (4 –14)11 (6 –16)6 (3 –10)13 (7 –18)Administrative loss to follow-up, n (%)1432 (3.7%)107 (2.8%)297 (3.8%)253 (2.1%)775 (5.3%) Substance use identified from one year prior to first pregnancy-related healthcare contact to date of delivery, n (%) Alcohol use12857 (33.2%)743 (19.5%)7,781 (100%)-----4,333 (29.4%)Cannabis use16994 (43.9%)770 (20.3%)-----12,329 (100%)3,895 (26.4%)Stimulant use5534 (14.3%)1,435 (37.7%)----------4,099 (27.8%)Other substances14643 (37.9%)2,936 (77.2%)----------11,707 (79.3%) OAT during pregnancy, n (%) -----2,106 (55.4%)---------------1st trimester-----1,547 (40.7%)---------------3rd trimester-----1,892 (49.8%)--------------- Comorbidities at time of delivery, n (%) Chronic pain, non-cancer16094 (41.6%)1,983 (52.1%)2,886 (37.1%)5,297 (43.0%)5,928 (40.2%)Gestational diabetes2296 (5.9%)173 (4.6%)428 (5.5%)995 (8.1%)700 (4.7%)Carlson comorbidity index > 1 within past 4 years21269 (3.3%)349 (9.2%)161 (2.1%)205 (1.7%)554 (3.8%) Mental health disorders at time of delivery 3 , n (%) 23523 (60.8%)3,060 (80.5%)3,745 (48.1%)7,392 (60.0%)9,326 (63.2%)Anxiety disorders13868 (35.9%)2,296 (60.4%)2,088 (26.8%)4,006 (32.5%)5,478 (37.1%)Non-major depression or other mood disorders11826 (30.6%)1,869 (49.2%)1,695 (21.8%)3,284 (26.6%)4,978 (33.7%)Psychotic disorder4907 (2.3%)237 (6.2%)80 (1.0%)137 (1.1%)453 (3.1%)Behavioural disorder2532 (6.5%)389 (10.2%)265 (3.4%)881 (7.2%)996 (6.8%)Personality disorder1997 (5.2%)458 (12.0%)194 (2.5%)365 (3.0%)980 (6.6%)Other disorder52151 (5.6%)369 (9.7%)296 (3.8%)589 (4.8%)897 (6.1%)Serious mental illness3365 (8.7%)600 (15.8%)447 (5.7%)843 (6.8%)1,475 (10.0%)Major depressive disorder3102 (8%)546 (14.4%)425 (5.5%)760 (6.2%)1,371 (9.3%)Bipolar disorder953 (2.5%)184 (4.8%)91 (1.2%)193 (1.6%)485 (3.3%)Schizophrenia545 (1.4%)139 (3.7%)42 (0.5%)81 (0.7%)283 (1.9%)Indication of self-harm3234 (8.4%)602 (15.8%)475 (6.1%)587 (4.8%)1,570 (10.6%) Healthcare utilization within 12 months prior to delivery, n (%) Any hospitalizations8433 (21.8%)1,366 (35.9%)1,397 (18.0%)1,808 (14.7%)3,862 (26.2%)Any emergency department visits20304 (52.5%)2,323 (61.1%)3,664 (47.1%)7,256 (58.9%)7,061 (47.9%) Pregnancy outcomes at delivery Stillbirth257 (0.7%)38 (1.0%)44 (0.6%)62 (0.5%)113 (0.8%)Caesarean section11455 (29.6%)1,290 (33.9%)2,166 (27.8%)3,820 (31.0%)4,179 (28.2%)1. Any indication of perinatal substance use excluding opioids but including alcohol or cannabis when other substances were also identified. 2. Past four years is provided since historical follow-up begins January 1st 1996, but perinatal data starts from April 1st 2000. 3. Specific conditions will add up to more than total as 10,481 (27.1%) of mothers had more than 1 mental health disorder. 4. Excluding schizophrenia. 5. Includes developmental disorders and other childhood onset disorders, personality and psychotic disordersAbbreviations: OAT: Opioid agonist treatment.All variables are defined in Supplementary S1 Table and S2 Table.*Birth data available until March 31, 2022. Descriptive statistics of mothers in BC with indication of substance use between one year prior to first pregnancy-related healthcare contact and date of delivery, by substance type (2000/04/01-2022/12/31*). 1. Any indication of perinatal substance use excluding opioids but including alcohol or cannabis when other substances were also identified. 2. Past four years is provided since historical follow-up begins January 1st 1996, but perinatal data starts from April 1st 2000. 3. Specific conditions will add up to more than total as 10,481 (27.1%) of mothers had more than 1 mental health disorder. 4. Excluding schizophrenia. 5. Includes developmental disorders and other childhood onset disorders, personality and psychotic disorders Abbreviations: OAT: Opioid agonist treatment. All variables are defined in Supplementary S1 Table and S2 Table. *Birth data available until March 31, 2022. Available data Demographic characteristics, clinical characteristics, and healthcare utilization. Demographic data are captured on age, location, receipt of income assistance, housing stability at the time of delivery, incarceration in provincial institutions, and death. Clinical data are collected for all hospitalizations, physician billing, emergency department visits, maternal and newborn health outcomes, and drug dispensations. These data allow us to measure healthcare utilization and clinical outcomes, both during pregnancy and until the end of data capture (i.e., December 31, 2022), for both mothers and their children. Available data include health records related to acute and chronic conditions, mental health diagnoses, and substance use disorder diagnoses. Novel measurements. The unique linkages between mothers and their children over time allows us to measure the ways in which maternal health outcomes and life events may affect child health outcomes. For example, in our cohort, mother and child separations are only captured if the separation occurs at discharge from hospital. Later separations can be inferred based on the geographic location of the mother and child in their individual health records (available in multiple component datasets; subject to evaluations of concordance) or by assessing whether a mother-child pair are attached to the same social assistance record. This information can then be used to evaluate the association between such separations and adverse physical and mental health outcomes for both mother and child. Importantly, our data do not distinguish between separations where a child is placed in kinship care (i.e., with a family member) versus foster care, nor can we distinguish between separations made by choice versus state apprehension. Similarly, although direct linkages to non-birthing parents (e.g., fathers, stepparents) are unavailable, in instances where the non-birthing parent is part of the broader provincial substance use cohort, [32] these individuals are linked to their children or the mothers via social assistance records. The longitudinal nature of our data also allows us to evaluate trends in maternal and child health outcomes over time, enabling the exploration of the impact of specific events, such as the COVID-19 pandemic, the end of birth alerts in 2019, and the introduction of fentanyl into the unregulated drug supply. Ethical approval This study has been determined to meet the criteria for exemption per Article 2.5 of the 2018 Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. Study databases have been made available by the BC Ministries of Health and Mental Health and Addiction as part of the provincial opioid overdose public health emergency response. All data in the cohort are de-identified, and patient consent for the secondary use of these data was not required. Results Demographic and clinical characteristics The demographic and clinical characteristics of mothers and children in the population-based cohort are described in Table 1 and Table 2, respectively. Of the 38,670 mothers with an indication of substance use between 12 months prior to first pregnancy-related healthcare contact and time of delivery, 31.9% (n = 12,329) used cannabis only. A total of 3,803 mothers (9.8%) had an indication of opioid use during this time period. 10.1371/journal.pone.0348262.t002Table 2Descriptive statistics of children born to mothers in BC with indication of substance use between 12 months prior to first pregnancy-related healthcare contact and time of delivery by substance type (2000/04/01-2022/12/31*).Any substancesOpioidsAlcohol onlyCannabis onlyOther substances1(N = 45,823)(N = 5,042)(N = 8,661)(N = 15,200)(N = 16,920)Age at end of data capture, years**9 (4 –14)8 (4 –13)10 (6 –15)6 (3 –9)13 (7 –17)Administrative loss to follow-up, n (%)1,466 (3.2%)113 (2.2%)311 (3.6%)295 (1.9%)747 (4.4%)Death during follow-up, n (%)468 (1.0%)84 (1.7%)90 (1.0%)78 (0.5%)216 (1.3%) Mother’s death during follow-up, n (%) 1,524 (3.3%)377 (7.5%)277 (3.2%)115 (0.8%)755 (4.5%)Death within first year of life133 (0.3%)52 (1.0%)13 (0.2%)11 (0.1%)57 (0.3%)Death prior to age 5531 (1.2%)174 (3.5%)69 (0.8%)56 (0.4%)232 (1.4%) Ever identified as separated from mother, n (%) 27,514 (60.0%)3,967 (78.7%)4,553 (52.6%)6,979 (45.9%)12,015 (71.0%)Separated from hospital discharge1,927 (4.2%)609 (12.1%)111 (1.3%)107 (0.9%)1,110 (6.5%)Separation identified from SDPR213,552 (29.6%)2,913 (57.8%)1,723 (19.9%)2,338 (15.4%)6,578 (38.9%)Separation identified from mismatched location224,812 (54.1%)3,427 (68.0%)4,211 (48.6%)6,196 (40.8%)10,978 (64.9%)Separation due to incarceration of mother2,736 (6.0%)801 (15.9%)240 (2.8%)176 (1.2%)1,519 (9.0%)Any mental health disorder diagnosis3, n (%)12,053 (26.3%)1,749 (34.7%)2,039 (23.5%)2,230 (14.7%)6,035 (35.7%)Anxiety, depression or other mood disorder45,848 (12.8%)635 (12.6%)1,168 (13.5%)554 (3.6%)3,491 (20.6%)Developmental disorder3,128 (6.8%)614 (12.2%)461 (5.3%)639 (4.2%)1,414 (8.4%)Behavioral disorder6,408 (14%)1,011 (20.1%)929 (10.7%)1,196 (7.9%)3,272 (19.3%)Other mental health condition53,310 (7.2%)542 (10.8%)511 (5.9%)688 (4.5%)1,569 (9.3%)Serious mental health disorder61,006 (2.2%)108 (2.1%)192 (2.2%)40 (0.3%)666 (3.9%)Incidence of self-harm1,189 (2.6%)146 (2.9%)209 (2.4%)75 (0.5%)759 (4.5%)Incidence of child maltreatment or peer violence7,047 (15.4%)910 (18.1%)1,393 (16.1%)1,681 (11.1%)3,063 (18.1%) Psychiatric prescription medications, n (%) Benzodiazepines1,911 (4.2%)205 (4.1%)419 (4.8%)215 (1.4%)1,072 (6.3%)Antipsychotics or antimanic1,711 (3.7%)227 (4.5%)280 (3.2%)134 (0.9%)1,070 (6.3%)SSRIs or other antidepressants3,907 (8.5%)404 (8.0%)791 (9.1%)223 (1.5%)2,489 (14.7%)Stimulants4,972 (10.9%)782 (15.5%)764 (8.8%)825 (5.4%)2,601 (15.4%) Acute care utilization, n (%) Any hospitalizations18,184 (39.7%)2,306 (45.7%)3,606 (41.6%)4,389 (28.9%)7,883 (46.6%)Any emergency department visits**5 (2 –11)6 (2 –11)6 (2 –12)4 (1 –8)7 (2 –14) Birth outcomes Gestational age**39 (37 –40)38 (36 –39)39 (38 –40)39 (37 –40)39 (37 –40)Preterm, n (%)7,010 (15.3%)1,317 (26.1%)1,028 (11.9%)1,985 (13.1%)2,680 (15.8%)Birth weight (grams)**3312 (2943–3670)3096 (2700–3470)3424 (3075–3760)3320 (2965–3660)3310 (2930–3670)Low birth weight, n (%)4,154 (9.1%)844 (16.7%)528 (6.1%)1,199 (7.9%)1,583 (9.4%)Small for gestational age and related conditions, n (%)8,232 (18.0%)1,734 (34.4%)1,112 (12.8%)2,392 (15.7%)2,994 (17.7%)*Birth data available until March 31, 2022. **Median (1st quartile – 3rd quartile).1. Any indication of mother’s substance use excluding opioids but including alcohol or cannabis when other substances were also identified2. Multiple methods were used to estimate the number of separations in the cohort; these estimates should not be added together. Only one instance of separation was counted per child.3. Specific conditions will add up to more than total as 5,020 (11.0%) of children had more than 1 mental health disorder.4. Excluding major depressive disorder5. Includes other childhood onset disorders, personality and psychotic disorders6. Includes major depressive disorder, bipolar disorder, and schizophrenia Descriptive statistics of children born to mothers in BC with indication of substance use between 12 months prior to first pregnancy-related healthcare contact and time of delivery by substance type (2000/04/01-2022/12/31*). *Birth data available until March 31, 2022. **Median (1st quartile – 3rd quartile). 1. Any indication of mother’s substance use excluding opioids but including alcohol or cannabis when other substances were also identified 2. Multiple methods were used to estimate the number of separations in the cohort; these estimates should not be added together. Only one instance of separation was counted per child. 3. Specific conditions will add up to more than total as 5,020 (11.0%) of children had more than 1 mental health disorder. 4. Excluding major depressive disorder 5. Includes other childhood onset disorders, personality and psychotic disorders 6. Includes major depressive disorder, bipolar disorder, and schizophrenia The median age at delivery among mothers was 27 years (interquartile range [IQR]: 22–32). Nearly half of mothers (n = 18,655, 48.2%) had received income assistance prior to the birth of their first child in the cohort. Across categories of prenatal substance exposure, individuals with an indication of prenatal opioid use had the highest rates of unstable housing (n = 581, 15.3%) and receipt of income assistance (n = 3,035, 79.8%) at any point prior to delivery, and the highest rates of diagnoses for chronic pain, comorbidities, emergency room visits, and hospitalizations during the follow-up period (Table 1). Among the 45,823 children in the population-based cohort, 15.3% (n = 7,010) were born preterm (i.e., < 37 weeks’ gestation), and 9.1% (n = 4,154) were born with low birthweight (i.e., < 2,500g). These rates are higher than those identified among the broader BC population (preterm birth: 11.6%; low birthweight: 4.9%).[33] These adverse outcomes were particularly common among children born to mothers with an indication of opioid use (Table 2). A total of 4.2% (n = 1,927) were separated from their mothers at hospital discharge. Using the SDPR database, 29.6% (n = 13,552) of children experienced separation from their mothers during ≥1 calendar month over the follow-up period (Table 2). Concurrent mental health conditions Prior to delivery, major depressive disorder was identified in 8.0% of mothers overall (n = 3,365). Indications of self-harm were documented among 8.4% of mothers (n = 3,234). Mental health disorders were present among 26.3% of children over the course of follow-up (n = 12,053) and over 40% of children with ≥16 years of follow-up (Fig 2). The most common diagnoses in children were anxiety, depression, or other mood disorders (n = 5,848, 12.8%) (Fig 2). Mental health diagnoses among children born to mothers with perinatal substance use from ages 4 to 18 1. Includes depression (not major depressive disorder), mood and anxiety disorder. 2. Includes major depressive disorder, bipolar disorder, and schizophrenia. 3. Includes other childhood onset disorders, personality and psychotic disorders. Maternal mortality During the follow-up period, 1,387 maternal deaths were recorded, representing 3.6% of the total cohort. From 2004–2022, the rate of maternal deaths per 1000 people increased from 2.0 to 5.6, with a substantial increase observed starting in 2016, when a public health emergency was declared in BC due to escalating numbers of drug poisoning-related deaths caused by the saturation of fentanyl in the unregulated drug supply (Fig 3). Indeed, drug-related causes were a major contributor to maternal mortality in this cohort, with a noticeable increase in the proportion of deaths attributed to drug-related causes beginning in 2016 (Fig 3). Notably, a total of 358 deaths occurred among mothers with an indication of opioid use during the follow-up period, representing 9.4% of these mothers. A total of 133 children (0.3%) experienced the death of their mother within the first year of life, and 531 (1.2%) experienced this loss within the first five years of life. Maternal deaths between 2000/04/01–2022/12/31. The increase in the proportion of deaths due to unknown causes since 2019 is due to a lag in data availability. Discussion In this cohort profile, we detail construction of a population-based cohort of mothers with SUD and their children, describing key characteristics and the breadth of data available. The major strength of this cohort is its longitudinal, population-based design, which allows us to capture data spanning over two decades from all individuals in the province with a record of prenatal substance use. In addition, as the cohort is updated annually, our analyses can be updated periodically to explore long-term maternal-child health outcomes, and to investigate the impact of factors such as policy changes, changes in the unregulated drug supply, or acute public health events (e.g., COVID-19). Our ability to link data from ten health administrative databases also offers detailed insights into the healthcare system’s successes or failures to provide cohort members with healthcare and social services, and how this engagement impacts clinical outcomes over time. The ability to link maternal-child records permits investigation of how systemic health inequities shape maternal experiences of disadvantage (e.g., mental health disorders, inadequate housing, forced separation) and how these experiences may impact child health and development. Limitations There are also several limitations. As health administrative datasets are primarily intended for reimbursement rather than research purposes, some important information cannot be captured, including health events for which healthcare was not received, as well as social factors (e.g., socioeconomic status, employment, adverse childhood events). Future research should aim to address these gaps through prospective, participatory, qualitative research. Importantly, the datasets do not contain direct observations of substance use, either through self-report or urine drug testing. This means that individuals without an indication of substance use in their health administrative records may be missing from the cohort. Moreover, our classifications of substance use disorders and administrative loss to follow-up may result in misclassification. We will consider alternative thresholds to assess the robustness of results to these thresholds. Our data are also not linked to data from the BC Ministry of Child and Family Development, meaning we are unable to identify children separated by state apprehensions. There were also 3,102 children who could not be linked to their mothers. These children included twins whose records could not be distinguished from one another, and children with missing linkage information. This limitation will be addressed in a forthcoming data update. With the exception of individuals who are in the broader substance use cohort, our population-based cohort does not currently contain information on fathers or other non-birthing parents. This limitation will also be mitigated in a future data update. There are also limitations within the datasets. The PharmaNet database does not capture medications dispensed in hospital, and is missing costing information for claims paid by the Canadian federal government, as well as antiretroviral medications.[34] Similarly, the Medical Services Plan database do not capture billing records under the Alternative Payment Plan, most often associated with community health centres.[35] Lastly, many harm reduction services, which are an important part of the continuum of care for individuals who use substances, [36] do not require individuals to provide identifying information in order to use these services. As a result, these interactions are not captured in provincial databases. Further linkage to community and local services is necessary to characterize health care service utilization, including the use of peer support services. Conclusion The growing population of mothers with substance use disorder represent a critical need for the province of British Columbia. This population-based retrospective cohort will be used to inform service design and otherwise advocate for client needs. Supporting information Data collection timeline for each provincial administrative database (01/01/1996-31/12/2022). MSP, Medical Services Plan; DAD, Discharge Abstract Database; BCVS, BC Vital Statistics; PNET, Pharmanet; PSBC, Perinatal Services BC; SDPR, BC Social Development and Poverty Reduction; NACRS, National Ambulatory Care Reporting System; BCCS, BC Coroners Service; BC Corrections, BC Provincial Corrections. (DOCX) Description of ten provincial administrative database in British Columbia, 2000–2022. Abbreviations: DIN: Drug Identification Number; PIN: Product Identification Number; † Coding structures used by the Canadian Institute of Health Information. (DOCX) Case finding algorithm of substance use, comorbidities, other conditions, and social determinants of health. AHFS: American Hospital Formulary Service by the American Society of Health-System Pharmacists; BCPDR: British Columbia Perinatal Data Registry; DAD: Discharge Abstract Database (hospitalizations); DIN: drug identification number in PharmaNet (drug dispensations); ICD-9-CA: International Classification of Diseases, Ninth Revision, Canada. ICD-10-CA: International Statistical Classification of Diseases and Related Health Problems, Tenth Revisions, Canada; MSP: Medical Services Plan; NACRS: National Ambulatory Care Reporting System (emergency department visits); PIN: product identification number in PharmaNet (drug dispensations); SDPR: Social Development and Poverty Reduction; VS: Vital Statistics database in British Columbia (death records). a Diacetylmorphine or hydromorphone with some restrictions based on prescriber, dispensing pharmacy and/or date. *Pharmacare Plan C (Income Assistance) provides full coverage of eligible prescription costs for B.C. residents receiving benefits and income assistance through the Ministry of Social Development and Poverty Reduction, or in the care of, or in an agreement with Ministry of Children and Family Services for children and youth. (DOCX) 18 Feb 2026 -->PONE-D-25-53902-->-->Cohort profile: mothers who use substances and their children in British Columbia, Canada-->-->PLOS One Dear Dr. Nosyk, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. -->-->Thank you for your patience with the peer review. The manuscript is timely and well-written. I have reached a final decision of "minor revision".-->--> Please submit your revised manuscript by Apr 04 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:--> A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. -->If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, David T. Zhu Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. 6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions -->Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. --> Reviewer #1: Partly Reviewer #2: Yes ********** -->2. Has the statistical analysis been performed appropriately and rigorously? --> Reviewer #1: No Reviewer #2: N/A ********** -->3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.--> Reviewer #1: Yes Reviewer #2: Yes ********** -->5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)--> Reviewer #1: Reviewer Comments for Manuscript PONE-D-24-45499R3 This manuscript contains grammatical errors, awkward phrasing, and inconsistent tense usage that reduce clarity and readability. Several sentences are overly long or redundant, which weakens the logical flow of the argument. I recommend a thorough language edit to: • Correct grammar and typographical errors. • Ensure consistent use of past tense in the Methods and Results sections, and present tense in the Introduction and Discussion…(e.g., “effective coverage,” “crude coverage”) • Shorten or restructure overly long sentences to improve conciseness and readability. Minor typographical errors and redundancies should be carefully polished before publication. Suggestion: The manuscript would benefit significantly from thorough proofreading by a native English speaker or professional editing service to improve clarity and adherence to academic writing standards. 2. Abstract • The abstract is informative but needs refinement for clarity. • The study period is confusing: the abstract mentions June–July 2023 (1 month), while the methods section refers to September 2021–August 2022 (1 year). This inconsistency must be corrected. You have to remove … “using secondary data of mothers who received antenatal care from September 01, 2021, to August 30, 2022”. You have also change design into “retrospective cross-sectional studies”. Change…”bi variable logistic regression” → “bivariable logistic regression”; • The results section of the abstract should align with the operational definition of effective coverage. For example, if screening for gestational diabetes is required, how does the reported 25.9% coverage reconcile with only 8.2% receiving that service? 3. Introduction • The introduction is well contextualized, but some sentences are repetitive and could be streamlined. • The rationale for focusing on effective coverage rather than crude coverage is well stated, but the flow could be improved by reducing redundancy. • Consider clarifying the conceptual framework of effective coverage (need, use, quality) more succinctly. • Suggestion: Consider adding a sentence on why West Gojjam Zone specifically was chosen—e.g., known gaps in ANC quality, high maternal mortality, or representative setting. • Question: The authors state that “none have examined EC of ANC in our region especially in my study setting.” Were there any sub-national or facility-based ANC quality assessments that could be referenced for context? Methods Study design and period The description of the study design is somewhat confusing. The manuscript currently states: “A facility-based analytical cross-sectional study design was conducted in West Gojjam public hospitals from June 30 to July 30, 2023, utilizing secondary data from mothers who received antenatal care between September 1, 2021, and August 30, 2022.” • Since the data were extracted retrospectively from ANC charts, the design would be more accurately described as a retrospective cross-sectional study rather than “analytical cross-sectional.” • The phrase “utilizing secondary data from mothers who received antenatal care between September 1, 2021, and August 30, 2022” is redundant here, because the study population and source of data are already explained elsewhere. • I recommend that the authors simplify this section to report only the study design and data collection period, while clearly noting that secondary data were used. For example: “A facility-based retrospective cross-sectional study was conducted in West Gojjam public hospitals. Data were collected between June 30 and July 30, 2023, from ANC charts covering the period September 1, 2021, to August 30, 2022.” Sampling Size Calculation I appreciate that the authors calculated the sample size for both objectives (coverage and associated factors). However, including the full formula in the manuscript is not necessary, since you have already stated that the single population proportion formula was used. I recommend simplifying this section by: • Clearly stating that the sample size was calculated for both objectives. • Indicating that the largest sample size obtained was selected as the final sample size for the study. • Removing the redundant formula presentation, while keeping the assumptions (confidence level, margin of error, prevalence, design effect, non-response rate) clearly described. This will make the Methods section more concise and reader friendly, while still transparent about how the sample size was determined. Study Design and Sampling: • The multi-stage random sampling is appropriate, but the description of selecting 3 out of 8 hospitals (38%) by “lottery” is vague. Were all hospitals eligible? Was stratification considered? • Suggestion: Clarify whether the selection was truly random or purposive, and justify the sample size allocation. Why were only 3 hospitals selected? Was power considered at the hospital level? Why was a design effect of 1.5 applied? Was clustering expected, and if so, at what level? Please justify this choice. Measurement of Effective Coverage: The definition aligns with WHO recommendations, but the operationalization—“received all the WHO recommended interventions at least once”—may overlook frequency and timing of interventions, which is acknowledged as a limitation. Suggestion: Briefly note how missing data on intervention timing was handled. How was “adequately trained human power” assessed? Was it based on presence per shift, or per patient load? Clarify whether data were extracted only from charts or supplemented with interviews. Line 181-182. Avoid----remove…”The questionnaire was prepared in English and 182 pretested among 5% (34) of study population before the actual data collection”…this repetition/The author already included in data quality control. Data Analysis: The use of p<0.25 for inclusion in multivariable analysis is acceptable but should be justified given the sample size. Suggestion: Consider also using variance inflation factors (VIF) to check multicollinearity, especially among obstetric/gynecological variables. Question: Why were hospital-level factors (e.g., equipment, staffing) not included in the regression model? Results: Tables are comprehensive but could be better formatted. For example, Table 5 is split across pages Comment on Definition and Results of Effective Coverage The manuscript defines effective coverage of ANC interventions as: pregnant women who attended four or more ANC visits and received all WHO recommended interventions at least once during their ANC follow up period. However, the results presented raise important concerns: • For several interventions, the proportion of women receiving them “at least once” is far below 25.9%. For example, only 8.2% received antenatal ultrasound and 8.2% were screened for gestational diabetes mellitus. • If all WHO recommended interventions are required for effective coverage, then the reported 25.9% effective coverage seems inconsistent with these low uptake rates. • The table also mixes “at each visit” and “at least once” indicators, which makes interpretation difficult. For example, gestational diabetes screening is reported as 25.9% “at each visit” but only 8.2% “at least once.” This needs clarification. • The operational definition should be applied consistently: if “all WHO interventions at least once” is the criterion, then the effective coverage proportion should reflect the lowest uptake intervention (e.g., 8.2%). Recommendations: 1. Clarify the operational definition of effective coverage — is it “all WHO interventions at least once” or “some interventions at least once”? 2. Ensure consistency between the definition and the reported results. 3. Revise the Results section to avoid contradictory figures (e.g., 25.9% vs. 8.2%). 4. Consider presenting both crude coverage (ANC 4+) and effective coverage (ANC 4+ plus all WHO interventions) separately, with clear explanation. Discussion: The discussion appropriately contextualizes findings within existing literature and offers plausible explanations for discrepancies. To strengthen the impact of your manuscript, please revise the Discussion to move beyond restating the Results. Instead, focus on interpreting the clinical and public health significance of your key findings. For each major result, please address: 1. What does this mean for practice? (e.g., How should the very low rate of Gestational Diabetes Mellitus screening change clinical protocols or health worker training?) 2. What are the policy implications? (e.g., Does the finding that women with prior complications receive better coverage suggest a need to reallocate resources or change messaging to reach low-risk women?) 3. How can these findings inform action? Conclude with targeted, practical recommendations for health system managers and policymakers in your setting." Question: The finding that prior complications increase effective coverage suggests that risk-based care is occurring. Does this imply that low-risk women are being neglected? This has important programmatic implications. Reviewer #2: Review of "Cohort Profile: Mothers who use substances and their children in British Columbia, Canada" 16 February 2026 Lines 71-84 The authors might consider adding a brief description of substance treatment that exists outside the medical model, e.g. 12 Step and other peer-to-peer recovery programs, for clarity, and whether this is part of the studies being planned. Notably, this type of peer-to-peer delivery of services is a significant support for many people trying to recover from substance use disorders. Line 133 Consider changing "Tobacco use was not evaluated." to "Tobacco and caffeine use was not evaluated." or something similar, for additional clarity, and to help destigmatize drug use by highlighting that the majority of Canadian adults use substances, e.g. caffeine. Table 2 The table has two asterisked footnotes. Consider switching one of these to a different symbol, for clarity. Lines 278-279 Consider including indigenous and immigrant status in the list of social factors that may affect health outcomes, for clarity, and to highlight these differentials. Lines 301-304 The authors might consider adding a description of difficulty in including peer-to-peer recovery support below the text related to harm reduction services, for clarity. Supplemental Table 2 In the footnote, consider changing "... , or In the care of ..." to "... , or in the care of ..." to correct a typographical error. ********** -->6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.--> Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. --> 2 Apr 2026 Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf RESPONSE: Done, as requested. 2. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Before we proceed with your manuscript, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. RESPONSE: Unfortunately, de-identified data are not available for public access, according to the British Columbia Ministry of Health and the UBC Research Ethics Board. We have added this information in the disclaimer, page 2, line 29. A link to access data has been added on line 33. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible. Please update your Data Availability statement in the submission form accordingly. 3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. RESPONSE: We have now moved the ethical approval subsection to the end of the methods section, page 15, line 201. 4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. RESPONSE: Done, as requested. 5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. RESPONSE: Done, as requested. 6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. RESPONSE: Done, as requested. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions: Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Yes ________________________________________ 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: N/A ________________________________________ 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Comments from reviewer #1: Comments for Manuscript PONE-D-25-53902 I would like to commend the authors for their timely and important work in establishing a population-based cohort of mothers who use substances and their children in British Columbia. The study addresses a significant public health issue, and the cohort will serve as a valuable resource for future research aimed at improving maternal and child health outcomes in this vulnerable population. I also appreciate the editor for the opportunity to review this manuscript. General Comments The authors should carefully follow the PLOS ONE manuscript preparation guidelines. The current version lacks several required structural elements: • The Abstract is not fully structured. It should clearly include Methods, Results, and Conclusion sections in addition to the Background/Objective. • The main text does not contain a separate, structured Discussion and Conclusion section. At present, the manuscript ends abruptly without a clear synthesis of findings, interpretation and limitations • The Discussion should be organized to: o Summarize the principal findings. o Compare results with existing literature. o Address strengths and limitations. o Provide implications for practice, policy, and future research. • The Conclusion should be concise, highlighting the key message of the study. Without these sections, the manuscript does not meet the journal’s formatting and reporting standards. A thorough restructuring is required to ensure compliance and improve readability. Response: We have now relabelled and otherwise reorganized the paper to conform to journal standards. Introduction The introduction effectively sets the context by highlighting the rising rates of perinatal substance use (PSU) and associated adverse outcomes, particularly in British Columbia. The emphasis on systemic gaps in care and the impact of stigma is well-placed. Suggestion: Consider including a brief mention of the intersectional vulnerabilities faced by Indigenous and racialized communities in BC, which are noted later in the manuscript but could be introduced earlier to frame the urgency of the research. Question: The authors mention that PSU is under-researched due to ethical concerns and healthcare system failures. Could they elaborate on what specific ethical concerns have historically impeded research in this area? Response: disclosure and the potential for child removal. • Refer to structural barriers surrounding PSU population impeding their participation in research, particularly mothers. • Elaborate on impacts for other subgroups within this population (i.e., Indigenous people) Funding Statement Placement The authors currently places the funding information at the end of the Introduction, which is not consistent with the PLOS ONE guidelines. According to the journal’s requirements, funding details should be presented under a separate heading (e.g., Funding) in the appropriate section of the manuscript, not embedded within the Introduction. For example, instead of including text such as: “Funding for this cohort was obtained from the Health Canada Substance Use and Addiction Program (2223-HQ-000028; 1819-HQ-000036).” at the end of the Introduction, the authors should move this statement to a dedicated Funding section (usually after the Acknowledgments or before Competing Interests). Recommendation: • Provide a clear heading (Funding) in line with PLOS formatting. • Place the funding statement in the correct section, ensuring consistency with other required declarations (Competing Interests, Ethics Statement, Data Availability). • Keep the Introduction focused on background and rationale, without administrative details This applies to the Ethical Approval section as well. Response: Done, as requested. Methods Cohort Identification and Substance Use Definition: o The authors have used a 12-month window prior to the first pregnancy-related healthcare contact to identify substance use. While this approach aims to capture ongoing use, it may also include individuals with historical or sporadic use that is not necessarily active during pregnancy. o Suggestion: Consider discussing the potential for misclassification and how this may affect the cohort’s representativeness. Sensitivity analyses using narrower time windows (e.g., during pregnancy only) could strengthen the validity of substance use identification. o Question: Were any validation studies conducted to assess the accuracy of the case-finding algorithm in identifying active substance use during pregnancy? Response: Unfortunately, validation is not possible as no ‘gold standard’ measurement (ie. via self report) is feasible given the de-identified nature of the data. We have added the following to the discussion section (page 22, line 295): ““Moreover, our classifications of substance use disorders and administrative loss to follow-up may result in misclassification. We will consider alternative thresholds to assess the robustness of results to these thresholds.” Data Linkage and Missing Information: o The cohort links data from ten administrative databases, which is a strength. However, the absence of linkage to the BC Ministry of Child and Family Development is noted as a limitation, as it precludes identification of state-initiated child apprehensions. o Suggestion: The authors should elaborate on how they plan to address this in future updates, and whether partnerships with child welfare agencies are being pursued. o Question: What proportion of children in the cohort are estimated to be affected by child welfare involvement, and how might this bias the findings related to child separations? Response: We have pursued such partnerships and determined these data are not suitable for research purposes. Somewhat unbelievably, they are not collected systematically and availability of provincial health numbers are inconsistent. To our knowledge such data has never been used for research purposes. 2. Loss to Follow-up and Censoring: o The authors define administrative loss to follow-up as no health system contact for ≥66 months. While empirically derived, this cutoff may not fully capture individuals who have moved out of province or who disengage from healthcare due to stigma or systemic barriers. o Suggestion: Consider discussing alternative methods to ascertain vital status or out-of-province migration, such as linkage to national databases or mortality registries. o Question: Were there differences in demographic or clinical characteristics between those lost to follow-up and those retained? If so, how might this affect longitudinal analyses? Response: Linkage to datasets held outside the province of BC is not currently possible; such actions could only be taken by the provincial government, as only de-identified data is provided to researchers. We have noted this as a limitation on page 22, line 295: “Moreover, our classifications of substance use disorders and administrative loss to follow-up may result in misclassification. We will consider alternative thresholds to assess the robustness of results to these thresholds.” Measurement of Maternal-Child Separation: o The use of geographic mismatches and social assistance records to infer separations is innovative but indirect. The authors note that they cannot distinguish between voluntary separations, kinship care, and foster care. o Suggestion: Acknowledging this limitation is important, and future qualitative or mixed-methods studies could help contextualize these separations. o Question: How were inconsistencies between separation indicators (e.g., SDPR vs. geographic mismatch) resolved, and what is the estimated agreement between these measures? Response: This work is currently underway – we did not elaborate on details as we are assessing not only concordance between separation indicators, but also assessing use of geographic indicators from different component datasets within our linked data. We intend to report on this effort more exhaustively in forthcoming manuscripts, we have added the following (page 13, line 188): “Later separations can be inferred based on the geographic location of the mother and child in their individual health records (available in multiple component datasets; subject to evaluations of concordance) or by assessing whether a mother-child pair are attached to the same social assistance record.” Overall The methods are generally robust and well-described, and the cohort represents a significant contribution to perinatal substance use research. Addressing the above points will enhance the clarity, validity, and utility of the cohort profile for future users. Results • The descriptive tables are comprehensive and well-organized. The stratification by substance type is particularly useful. • Notable Findings: The high prevalence of mental health disorders among mothers (8%) and children (26.3%), along with the substantial rates of maternal mortality (3.6%) and child separation (60%), are striking and underscore the cohort's public health relevance. • Suggestion: In Table 1, consider presenting the proportion of mothers with polysubstance use (e.g., opioids + stimulants) to better characterize the complexity of substance use patterns. • Question: The median follow-up time varies substantially by substance type (e.g., 6 years for cannabis-only vs. 13 years for "other substances"). What might explain these differences, and how will the analyses account for varying follow-up durations? Response: RE: the suggestion – given the large extent of overlap and potential for many additional columns we chose to maintain the current table structure (which was in fact reduced from prior iterations in which combinations wer Submitted filename: Reviewer Comments for Manuscript PONE_final.docx 15 Apr 2026 Cohort profile: mothers who use substances and their children in British Columbia, Canada PONE-D-25-53902R1 Dear Dr. Nosyk, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, David T. Zhu Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: PONE-D-25-53902R1 PLOS One Dear Dr. Nosyk, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Mr. David T. Zhu Academic Editor PLOS One